Inhibitor Therapeutics, Inc.
Data quality: 83%
INTI
OTC
Manufacturing
Chemicals
$0.10
▲
$0.02
(25.00%)
Mkt Cap: 17.26 M
Price
$0.10
Mkt Cap
17.26 M
Day Range
$0.08 — $0.08
52-Week Range
$0.03 — $0.12
Volume
30,001
Open $0.08
50D / 200D Avg
$0.08
20.63% above
50D / 200D Avg
$0.06
72.41% above
Quick Summary
Key Takeaways
Negative free cash flow of -3.23 M
Growth
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Quality
Return on Equity
-917.92%
Below sector avg (-51.02%)
ROIC-79.44%
Net MarginN/A
Op. MarginN/A
Safety
Debt / Equity
N/A
Current Ratio35.00
Interest CoverageN/A
Valuation
PE (TTM)
-5.23
Below sector avg (-1.98)
P/B Ratio4997.79
EV/EBITDAN/A
Dividend YieldN/A
Price History
Financial Trends
Peer Comparison
vs Manufacturing sector median (44 peers)
Peer Comparison
vs Manufacturing sector median (44 peers)| Metric | Stock | Sector Median |
|---|---|---|
| P/E | -5.2 | -2.0 |
| P/B | 4997.8 | 5.1 |
| ROE % | -917.9 | -51.0 |
| Net Margin % | — | -150.2 |
| Rev Growth 5Y % | — | 9.3 |
| D/E | — | 0.3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -3.30 M |
| ROE | -917.92% | ROA | -93.72% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -3.23 M |
| ROIC | -79.44% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 35.00 |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | 2.98 M | Tangible Book Value | 3,453 |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -5.23 | Forward P/E | N/A |
| P/B Ratio | 4997.79 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -18.72% | ||
| Market Cap | 17.26 M | Enterprise Value | 14.28 M |
| Per Share | |||
| EPS (Diluted TTM) | -0.02 | Revenue / Share | N/A |
| FCF / Share | -0.02 | OCF / Share | -0.02 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 97.91% |
| SBC-Adj. FCF | -3.25 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | 0.0 |
| Net Income | -3.30 M | -3.34 M | -3.03 M | 12.11 M | -298,632.0 |
| EPS (Diluted) | -0.02 | -0.02 | -0.02 | 0.03 | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -3.43 M | -3.66 M | -3.40 M | -657,926.0 | -325,395.0 |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 1.70 M | 1.68 M | 1.38 M | 6,150.0 | 4,905.0 |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | — | — | — | — |
| Interest Expense | — | — | 23,234.0 | 23,234.0 | -14,837.0 |
| Income Tax | — | — | 55,109.0 | 55,109.0 | 0.0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 2.51 M | 5.69 M | 8.95 M | 11.98 M | 58,784.0 |
| Total Liabilities | 3.80 M | 3.71 M | 3.67 M | 3.68 M | 3.68 M |
| Shareholders' Equity | -1.29 M | 1.99 M | 5.28 M | 8.30 M | -3.62 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 2.38 M | 5.61 M | 8.84 M | 11.95 M | 30,626.0 |
| Current Assets | 2.45 M | 5.69 M | 8.95 M | 11.98 M | 58,784.0 |
| Current Liabilities | 766,330.0 | 709,618.0 | 665,164.0 | 678,782.0 | 679,630.0 |
{"event":"ticker_viewed","properties":{"ticker":"INTI","listing_kind":"stock","pathname":"/stocks/inti","exchange":"OTC","country":"US"}}